Smile Simulation & AI
Smile simulation is about to get crowded and competitive. Here is an honest set of predictions for what preview tools will look like by 2028 — more realism, more languages, deeper lab links, and a reckoning on honesty.
Simulated preview — a visualization aid, not a guaranteed outcome.
By 2028, smile simulation will be more realistic, more multilingual, more deeply linked to the lab, and under real pressure to be honest — and the tools that win will compete on trust and integration, not just on how pretty the image looks. These are predictions, not promises, offered in the same honest spirit as everything else here. Here is where preview tools are heading, and what the coming competition will reward.
Because a capability that was novel is becoming table stakes, and that always triggers competition. As believable smile previews stop being a differentiator and start being expected, tool-makers will fight on the next layers — realism, honesty, workflow integration, language, and trust. The clinics that adopted early will have a head start; the vendors will race to out-integrate and out-honest one another. “War” overstates the drama, but the direction is real: the easy differentiation of simply having a preview is ending, and the harder competition over how good, how honest, and how connected the preview is has begun. That competition should benefit clinics and patients.
Held to a confidence level, rather than sold as certainties, the trajectory looks like this.
| Prediction | Why | Confidence |
|---|---|---|
| Previews become table stakes | Believable image quality is commoditising | High |
| Deeper lab integration | The value moves to the hand-off, not the image | High |
| Multilingual, region-native tools | Cosmetic demand is global; language is friction | High |
| On-device / faster processing | Speed and privacy both push local | Medium |
| Honesty and labelling pressure | Regulators and patients will demand it | Medium–High |
| Consolidation of vendors | Table-stakes markets consolidate | Medium |
Note the confidence column: some of this is near-certain, some is a considered guess, and honest forecasting says which is which.
Because once every serious tool produces a believable image, “more realistic” stops winning cases. Realism is following the familiar path of a maturing capability: astonishing, then expected, then assumed. By 2028 the marginal value of a slightly sharper preview will be small, and the competition will move to what the preview does — how honestly it is framed, how cleanly it hands off to the lab, how well it fits the consult and the language of the patient. Clinics choosing a tool in 2028 will ask less “how good does it look” and more “how well does it work in my practice and how honestly does it behave.”
Because the enduring value of a preview is not the image the patient sees but the approved aesthetic target it carries to the people who build the case. As the image commoditises, the differentiation moves downstream to the hand-off — how faithfully the tool carries design intent to the lab, and how cleanly it does so without overstepping into the measurements and prescriptions that belong to clinicians. The tools that win the integration layer will be the ones that respect that boundary while making the aesthetic hand-off effortless. That is the whole thesis behind a lab report that carries the look and prints no measurements, set out in what a preview should hand your lab.
Because cosmetic demand is global and monolingual tools leave most of it on the table. A preview that speaks only English underserves the huge cosmetic markets of the Gulf, the Levant, and beyond, where patients decide in Arabic and on regional platforms. By 2028, region-native, multilingual tools will have a structural advantage, because meeting the patient in their own language at the moment of desire removes friction that a translated afterthought cannot. The clinics and vendors that treat Arabic-first and region-native as central rather than optional will be positioned where much of the growth actually is. The regional angle runs through the Gulf preview-landing combo.
Because pressure from patients and regulators will make overpromising expensive. As previews become ubiquitous and powerful, the risk of them being mistaken for guarantees grows, and both regulators and burned patients will push toward clear labelling, honest framing, and straight answers on data. Tools that treated honesty as central — every image a visualization aid, not a guarantee, plain data answers, no unearned badges — will be ahead of that curve; tools that leaned on hype will be exposed by it. Honesty is becoming not just the ethical choice but the durable competitive one, because trust is what survives when the novelty wears off. The honesty thesis runs through the state of AI in cosmetic dentistry.
Choose for where the field is going, not just where it is. Adopt a believable preview now for the case-acceptance benefit, but weight your choice toward the things that will matter in 2028: honest framing, clean lab integration, language and region fit, and a vendor candid about data and limits. A tool chosen purely on today's image quality may be a commodity by 2028; one chosen for honesty and integration will still be earning its place. Bet on trust and workflow, because those are what the coming competition will reward — and they are, not coincidentally, the right things to value anyway.
Want a preview tool built for where the field is heading, not just where it is? book a demo — qualified clinics get a trial set up personally after a short demo.
Book a 20-minute demo and leave with a 30-day pilot — 100 previews and 5 lab reports, no card.
Book a demo →